Please provide your email address to receive an email when new articles are posted on . CHICAGO — Visual acuity and anatomical improvements were achieved at all dose levels of nesvacumab combined with ...
DAEJEON, South Korea, Aug. 19, 2021 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, today ...
Acute lung injury caused by cell death, high and potentially toxic concentrations of oxygen (hyperoxia), and the resulting excess fluid in the lungs (pulmonary edema), may be controlled by modulating ...
AUSTIN, Texas, January 08, 2026--(BUSINESS WIRE)--Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases, today announced ...
Final overall survival in the phase 3 NETTER-1 study of lutetium-177-DOTATATE in patients with midgut neuroendocrine tumors. This is an ASCO Meeting Abstract from the 2021 ASCO Annual Meeting I. This ...
RELAY+: Exploratory study of ramucirumab plus gefitinib in untreated patients (pts) with epidermal growth factor receptor (EGFR)-mutated metastatic non-small cell lung cancer (NSCLC). This is an ASCO ...
Aging causes a reduction of the protein Tie2, a risk factor for increased intraocular pressure and glaucoma. In this experiment, one eye of mice lacking Ang1 and Ang2 was injected with the premixed ...
Hopes had not exactly soared high for Regeneron Pharmaceuticals Inc.'s combo pairing the angiopoietin2 (Ang2) antibody nesvacumab with approved Eylea (aflibercept), although "nobody would like it to ...
Regeneron acquired full exclusive rights to two families of antibodies invented at the company’s labs, but previously included in its antibody collaboration with Sanofi. Acquired by Regeneron were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results